SCI时时刷

search
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan
Monoclonal antibodies targeting interleukin (IL)-5 pathways have revolutionized the treatment expectations for eosinophili...
Aprocitentan: First Approval
Aprocitentan: First Approval
Aprocitentan (TRYVIO™) is a once-daily oral dual endothelin A (ETA) and B (ETB) receptor antagonist developed by Ido...
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned
The development of new medicines for systemic lupus erythematosus (SLE) has not addressed unmet clinical need, with only t...
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
Although dual antiplatelet therapy (DAPT) improves the outcomes of patients undergoing percutaneous coronary intervention ...
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions
Depression during the first year postpartum (postpartum depression) impacts millions of women and their families worldwide...
Drugs in Development to Treat IgA Nephropathy
Drugs in Development to Treat IgA Nephropathy
IgA nephropathy is a common glomerulonephritis consequent to the autoimmune response to aberrant glycosylated immunoglobul...
Ensitrelvir Fumaric Acid: First Approval
Ensitrelvir Fumaric Acid: First Approval
Ensitrelvir fumaric acid (Xocova®) is an oral SARS-CoV-2 main protease inhibitor developed by Shionogi for the treatm...
Tegileridine: First Approval
Tegileridine: First Approval
Tegileridine (艾苏特) is a small molecule μ-opioid receptor biased agonist developed by Jiangsu Hen...
Resmetirom: First Approval
Resmetirom: First Approval
Resmetirom (Rezdiffra™) is an oral thyroid hormone receptor-β (THR-β) agonist being developed by Madrigal ...
Cefepime/Enmetazobactam: First Approval
Cefepime/Enmetazobactam: First Approval
Cefepime/enmetazobactam (EXBLIFEP®), an intravenous (IV) antibacterial fixed-dose combination of a 4th generation cep...
Crovalimab: First Approval
Crovalimab: First Approval
Crovalimab (派圣凯®; PiaSky) is a humanized, anti-complement component C5 (anti-C5) recycling monoc...
Bimekizumab: A Review in Psoriatic Arthritis
Bimekizumab: A Review in Psoriatic Arthritis
Although several biological disease-modifying antirheumatic drugs (bDMARDs), including interleukin (IL)-17A inhibitors, ar...
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
The COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly 7 million deaths, according to th...
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease
Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and ...
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sa...
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Dr...
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
The sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several deg...
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Topical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in ...
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree®...
The Pharmacological Landscape for Fatty Change of the Pancreas
The Pharmacological Landscape for Fatty Change of the Pancreas
The quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medica...
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease
Perfluorohexyloctane ophthalmic solution (Miebo®) is a single-entity, water-, steroid- and preservative-free, first-i...
Dimdazenil: First Approval
Dimdazenil: First Approval
Dimdazenil (Junoenil®) is a small-molecule, oral, partial positive allosteric modulator of the gamma-aminobutyric aci...
Danicopan: First Approval
Danicopan: First Approval
Danicopan (Voydeya®) is an oral complement factor D inhibitor that is being developed by Alexion AstraZeneca Rare Dis...
Iptacopan: First Approval
Iptacopan: First Approval
Iptacopan (FABHALTA®) is an oral complement Factor B inhibitor developed by Novartis Pharmaceuticals for the treatmen...
Fidanacogene Elaparvovec: First Approval
Fidanacogene Elaparvovec: First Approval
Fidanacogene elaparvovec (PrBEQVEZ™) is an adeno-associated viral (AAV) vector-based gene therapy developed by Spark...
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials
Nonalcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver diseas...
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability
Currently, there are four monoclonal antibodies (mAbs) that target the cluster of differentiation (CD) 20 receptor availab...
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?
Tamoxifen, a cornerstone in the adjuvant treatment of estrogen receptor-positive breast cancer, significantly reduces brea...
Opioids for Acute Musculoskeletal Pain: A Systematic Review with Meta-Analysis
Opioids for Acute Musculoskeletal Pain: A Systematic Review with Meta-Analysis
To evaluate the efficacy of opioids for people with acute musculoskeletal pain against placebo. Systematic review and meta...
Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
Adult-Onset Still’s Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options
Adult-onset Still’s disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiki...